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Objective To determine the effects of placebo vs an encapsulated supplement of fruit and vegetable
juice concentrate (FVJC) on serum b-carotene levels, insulin resistance, adiposity, and subclinical inflammation
in boys.
Study design Thirty age-matched prepubertal boys (9 lean and 21 overweight (OW); age range, 6-10 years) were
studied. All participants received nutrition counseling andwere randomized to receive FVJC or placebo capsules for
6 months. Total cholesterol, triglycerides, lipid corrected b-carotene, serum retinol, glucose, insulin, retinol binding
protein-4, leptin, adiponectin, leptin-to-adiponectin ratio, high-sensitivity C-reactive protein, and interleukin-6 were
measured before and after the 6-month intervention. Homeostasis model assessment-insulin resistance (HOMA-
IR), acute insulin response to intravenous glucose, along with abdominal fat mass (dual-energy x-ray absorptiom-
etry) were also determined.
Results Baseline b-carotene concentrations correlated inversely with HOMA-IR, leptin-to-adiponectin ratio, and
abdominal fat mass (P# .01). FVJC intake increased b-carotene concentrations (P# .001) but did not influence ret-
inol or retinol binding protein-4. Retinol insufficiency <1.047 mMwas present in 18% of the entire cohort at baseline
and in 37% at 6 months. HOMA-IR decreased after supplementation in the OW cohort, when adjusted for percent
weight change (P = .014). The percent change in abdominal fat mass increased in the placebo group and decreased
in the FVJC group (P = .029).
Conclusions A 6-month supplementation with FVJC in the presence of nutritional counseling was associated
with an increase in serum b-carotene concentrations and a reduction in adiposity in conjunction with an improve-
ment in insulin resistance in OW boys. (J Pediatr 2012;161:58-64).
T
he US Department of Health and Human Services objectives for Healthy People 20101 and the latest Expert Panel on
Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report2
include a diet high in fruits and vegetables to promote health. Despite these and other public health recommendations,
few children meet the daily recommended intake of fruits and vegetables for various reasons.3 In this context, supplementation
of essential nutrients as an adjuvant to nutritional counseling therapy may be of importance. Cross-sectional studies in obese
children and adults report reduced lipophilic nutrients, including b-carotene and serum retinol (SR) concentrations, presum-
ably from either reduced intake of fruits and vegetables or entrapment in adipose tissue.4 Increased consumption of green leafy
vegetables, which are important dietary sources of carotenoids, has been associated with reduced risk for type 2 diabetes.5
Although the results of supplementation with single or a few combined vitamins have been mixed for disease prevention in
adults,6 the issue in children remains understudied.
Recent studies also suggest that there is a relationship between retinol binding protein-4 (RBP4), which carries all-trans ret-
inol to its target tissues, and obesity-related insulin resistance (IR) in both adults and children,7-10 whereas others have reported
conflicting data.11,12 RBP4 is produced primarily in the liver, and about 20% is produced in the adipocytes.13 In the liver, RBP4
secretion is dependent on retinoid availability, such that it is blocked in times of liver retinol deficiency and restored on reple-
tion.13 Despite SR being a major biological determinant of RBP4, few studies have assessed these levels concurrently in nutri-
tional intervention studies.9,10
This double-blind placebo-controlled study was designed to determine the effects of supplementation with an encapsulated
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AIR Acute insulin response
BMI Body mass index
FFQ Food frequency questionnaire
FVJC Fruit and vegetable juice
concentrate
HDL High-density lipoprotein
GDI Glucose disposal index
HOMA-IR Homeostasis model assessment-
insulin resistance
HS-CRP High sensitivity C-reactive protein
IR Insulin resistance
IL-6 Interleukin-6
L/A Leptin-to-adiponectin ratio
LCbC Lipid corrected b-carotene
OW Overweight
QUICKI Quantitative insulin sensitivity
check index
RBP4 Retinol-binding protein-4
SR Serum retinol
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Vol. 161, No. 1  July 2012serum b-carotene, retinol, RBP4, and adiposity in lean and
overweight (OW) boys. Change in serum b-carotene was
considered the primary outcomemeasure, and IR and factors
related to subclinical inflammation were studied as second-
ary outcomes.
Methods
The study was approved by the Institutional Review Com-
mittee at Wolfson Children’s Hospital, Jacksonville, Florida,
and conducted in accordance with the Declaration of Hel-
sinki. Written parental informed consent and child’s assent
were obtained for all participants on enrollment in the study.
Subjects received nominal monetary compensation for their
participation. The study was registered at ClinicalTrials.gov
(NCT00842543).
A total of 39 prepubertal boys (age range, 6-10 years) were
enrolled, and 30 completed the study (9 lean boys with body
mass index [BMI] #85% and 21 OW boys with BMI of
>85%). Subjects were recruited from the Nemours Endocri-
nology and Metabolism Clinic in Jacksonville, Florida, and
through approved advertising sent to neighboring pediatric
clinics.
Subjects with a history of chronic illness or chronic medi-
cations were excluded from the study. To avoid illness-
related acute changes in the markers of interest, subjects
were studied only if they had no history of recent illness or
bone fracture within 2 weeks of their blood draw. They
were instructed not to consume any medications, including
vitamins, herbal remedies, or anti-inflammatory drugs,
within 30 days of the anticipated blood draw.
The intent-to-treat principle was applied to 39 subjects
who were randomized using a randomization scheme gener-
ated with use of the website Randomization.com (http://
www.randomization.com) and received either active supple-
ment or identical placebo capsules provided by the manufac-
turer (Juice Plus+; NSA, LLC, Collierville, Tennessee) in
conjunction with 6 months of nutritional counseling.
The study protocol is summarized in Figure 1 (available
at www.jpeds.com). History and physical exams were
performed including sitting blood pressure measured 3
times with an automated sphygmomanometer. Tanner
staging based on pubic hair and genitalia was performed in
all subjects. Waist circumference was measured to the
nearest centimeter with a flexible steel tape while the
subjects were standing, after gently exhaling, at the minimal
circumference measurable on the horizontal plane between
the lowest portion of the rib cage and iliac crest. A digital
scale and Harpenden stadiometer were used to measure
height and body mass and then to calculate BMI (kg/m2).
All subjects underwent a modified rapid intravenous
glucose tolerance test at baseline and at the end of the study
using 0.5 g/kg glucose (25% dextrose, maximum 25 g)
infused over 3 minutes, and blood was obtained at baseline
and 3 and 5 minutes after glucose administration.
A dual-energy x-ray absorptiometry scan was performed
to measure body composition (Hologic Discovery A 45903;Hologic Inc, Bedford, Massachusetts). Percent body fat, total
body fat, trunk fat, and abdominal fat mass values were ob-
tained. The abdominal region of interest was defined manu-
ally by adjusting the lines of the right rib box (standard
software option) between the upper L1 and lower L4 border
and the inner costal margin of the whole body scan following
the protocol used by Svendsen et al.14 The coefficients of var-
iation of the total body, trunk, and abdominal fat mass have
been reported at 1.4%, 3.6%, and 4.7%, respectively.15
All subjects had nutrition counseling sessions at baseline
and 3 months with a registered research dietician, targeted
to achieve improvement in the consumption of fruits and
vegetables and physical activity. All participants were in-
structed to take 1 study capsule daily with breakfast and
dinner. Two active capsules of FVJC provided approxi-
mately 3.75 mg of b-carotene, 117 mg of vitamin C, 22.5 IU
of vitamin E, 210 mg of folate, 30 mg of calcium, and 21 kJ
per day. The FVJC consist of orchard blendwith apple, orange,
pineapple, cranberry, peach, acerola cherry, and papaya and
garden blendwith carrot, parsley, beet, kale, broccoli, cabbage,
spinach, and tomato. Dietary composition andmicronutrient
intake were assessed using a modified 122-item, validated
food frequency questionnaire administered by the dietician.16
Estimates of nutritional intake were quantified with the use of
the nutrition analysis program Food Processor (version 9.3.0)
developed by ESHA Research (Salem, Oregon). Physical
activity was quantified based on the previous week’s activity
levels at school or home or during leisure time.
Blood was collected after 10 hours of fasting and processed
under orange lights immediately after collection—aliquots of
serum and plasma were frozen in opaque tubes at 80C
until analysis. Methods for measurement were as follows:
glucose (hexokinase), insulin (chemiluminescent immuno-
metric assay), total cholesterol, triglycerides, and high-
density lipoprotein (HDL) cholesterol concentrations
(colorimetric assay), b-carotene and SR (reverse-phase
high-performance liquid chromatography with photodiode
array detection between 220-600 nm as previously de-
scribed17), RBP4 and interleukin-6 (IL-6) (enzyme-linked
immunosorbent assay), high-sensitivity C-reactive protein
(HS-CRP) (immunonephelometry; Siemens Healthcare Di-
agnostics, Deerfield, Illinois), and adiponectin and leptin
(radioimmunoassay; Linco Research, St Charles, Missouri).
The homeostasis model assessment-insulin resistance
(HOMA-IR) was calculated using the formula: fasting
glucose (mM) fasting insulin (mU/mL)/22.5. The quantita-
tive insulin sensitivity check index (QUICKI) was calculated
as 1/[log10(fasting insulin in mU/mL) + log10(fasting glucose
in mg/dL)].18 The acute insulin response (AIR) was defined
as the mean incremental rise in plasma insulin at 3 and 5
minutes after a rapid intravenous glucose load. To adjust
AIR for the effects of insulin sensitivity, a glucose disposal
index (GDI) was calculated as log10(AIR  fasting glucose
concentration/fasting insulin concentration) in SI units.19
b-carotene concentration is closely correlated with major
lipid distribution and was corrected for lipid status (LCbC)
by dividing by the sum of total cholesterol and triglycerides59
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calculated by dividing the serum concentrations of RBP4
(mM) by retinol (mM). The molar ratio of leptin-to-
adiponectin (L/A) was calculated by dividing leptin (in
ng/mL) by adiponectin (in mg/mL). The fat mass index was
calculated by dividing the total body fat (in kg) from dual-
energy x-ray absorptiometry by the height (in m2).
Weight gain velocity for all participants was calculated as
grams per month at 3-month intervals. Actual weight velocity
minus the expected weight velocity for age- and weight-
matched normalized data21 was used to identify changes.
The data are presented in quartiles of percent change in
actual weight gain from expected weight gain (0%) at 3
months and 6 months for all subjects in Figure 2 (available
at www.jpeds.com).
Statistical Analysis
The intention-to-treat principle was applied to all subjects
included in the primary analysis. Baseline, demographic,
and other clinical characteristics are presented in Table I
and the same for the intervention groups in Table II
(available at www.jpeds.com). Quantitative variables are
presented using either mean with SD or, in the case of
substantially skewed distribution, median and IQR.
Categorical variables are presented using frequencies and
percentages. Two-sample t test or a nonparametric Mann-
Whitney U test, whichever is appropriate, is used to
compare quantitative variables, and c2 test/Fisher exact test
are used to compare the percentages between 2 groups.
Wilcoxon signed-rank test was used for paired sample
comparisons of nonparametric variables.Table I. Baseline clinical and biochemical
characteristics of study subjects by BMI group*†
Lean group
(n = 13)
OW group
(n = 26)
P
value
Age (y) 9.36 1.31 9.04 1.43 NS
BMI Z-score 0.08 1.43 2.14 0.47 <.05
Waist/height ratio 0.42 0.03 0.59 0.07 <.05
Fat mass index (kg/m2) 3.39 0.68 9.83 2.68 <.05
Abdominal fat mass (kg) 1.249 0.391 4.144 0.141 <.05
Systolic blood pressure
(mm Hg)
110 10 109 23 NS
b-carotene (mM) 0.29 (0.16-0.36) 0.22 (0.12-0.26) NS
SR (mM) 1.17 (1.0-1.27) 1.41 (1.12-1.58) .019
LCbC (mM) 0.055 (0.038-0.093) 0.035 (0.023-0.066) .04
RBP4 (mM) 1.02 (0.89-1.31) 1.26 (1.01-1.45) NSz
Insulin (pM) 43.9 (30.5-65.2) 98.7 (66.7-133.1) <.001
HDL (mM) 1.27 (1.07-1.45) 1.06 (0.85-1.29) .034
Triglycerides (mM) 0.52 (0.37-0.75) 0.96 (0.61-1.20) .004
HOMA-IR 1.34 (0.8-1.82) 3.68 (1.98-4.01) <.001
QUICKI 0.37 0.03 0.33 0.04 .003
AIR 345 (206-597) 687 (402-1014) .014
GDI 1.67 0.30 1.50 0.25 NS
HS-CRP (mg/L) 0.36 (0.16-0.39) 0.93 (0.38-0.93) .01
IL-6 (pg/mL) 0.69 (0.64-1.07) 1.35 (0.92-2.3) .018
Leptin (ng/mL) 3.76 (2.5-4.8) 21.3 (10.6-26.5) <.001
Adiponectin (mg/mL) 14.7 (10.8-20.9) 10.7 (7.6-12.4) .04
L/A 0.23 (0.19-0.31) 1.85 (1.02-2.67) <.001
*Mean SD (all appropriate values).
†Median (IQR) (all appropriate values).
zP = .084.
60The percent changes in concentrations from baseline at
3 and 6 months are presented in Table III (available at
www.jpeds.com). Repeated-measures subgroup analysis was
performed among OW children to compare the mean
changes in natural log-transformed HOMA-IR and
QUICKI over time (3 months and 6 months) as response
variables, and the intervention group was used as the
independent variable. Both models were adjusted for
a principal component of baseline values of the
corresponding variable and the percent change in weight
presented in Table IV. All tests were 2 tailed at the level of
significance of .05. The statistical software SPSS version
19.0 (SPSS, Chicago, Illinois) was used for analyses.
Results
Of the 246 children screened for eligibility, 74 did not meet
criteria, 35 refused to participate, 98 were not randomized
for various reasons, 39 were randomized, and 9 dropped
out before completion of the study. Pill count data were
available for 88% of all supplement bottles dispensed. At 3
months, 60% of the lean and 55% of the OW took >75%
of the active supplement capsules, and at 6 months 80% of
the lean and 50% of the OW children had >75% compliance.
However, the groups were not statistically different.
The clinical and biochemical characteristics of the study
participants by BMI and treatment groups are presented
in Tables I and II, respectively. By design, significant
differences between the lean and OW groups exist at
baseline in terms of adiposity including BMI Z-score, waist
circumference, waist-to-height ratio, fat mass index, and
abdominal fat mass (P# .05; Table I). There were no
differences between the treatment and placebo groups at
baseline (Table II).
None of the study subjects at baseline met the definition
for vitamin A deficiency (SR levels <0.7 mM); however, vita-
min A insufficiency (all-trans retinol <1.047 mM) was present
in 18% at baseline and 37% at 6 months for the entire cohort.
LCbCwas lower (P = .04) and SR was higher (P = .019) in the
OW children compared with the lean children. RBP4 trended
to be lower in lean vs OW children (P = .084), whereas the ra-
tio of RBP4 to retinol was not different between these groups.
There was a highly significant overall treatment effect be-
tween FVJC and placebo in the percent change in b-carotene
(P = .001) for the entire cohort but not for the percent change
in SR, RBP4, or RBP4-to-SR ratio. At 6 months, serum b-car-
otene increased by 303% 85% in the FVJC-treated lean
group, which was similar to the 334% 57% increase in
the OW group. However, in the placebo group, the percent
change in b-carotene increased only 23% 94% in the lean
and it decreased 30% 57% in the OW group (Table III).
Surprisingly, the rise in b-carotene was not accompanied by
a concomitant rise in SR or RBP4 levels in either the lean
or OW group (Table III). After 6 months of treatment, the
OW children showed a 1.9% decrease in RBP4 with FVJC
as opposed to a 9.5% increase with the placebo, which did
not reach statistical significance (P = .187; Table III).Canas et al
Table IV. Subgroup analysis of treatment effects of FVJC vs placebo in OW group for HOMA-IR and QUICKI at 3 and 6
months*†
FVJC group (n = 11) Placebo group (n = 10)
P value0 moz 3 mo 6 mo 0 moz 3 mo 6 mo
Log HOMA-IR 1.268 0.1 1.205 0.07 1.204 0.07 1.339 0.09 1.441 0.08 1.429 0.08 .014
QUICKI 0.336 0.01 0.341 0.01 0.341 0.01 0.326 0.01 0.313 0.01 0.315 0.01 .017
*Least squared mean SE (all appropriate values).
†Adjusted for percent change in body weight.
zP value between FVJC and placebo at 0 mo is not significant.
July 2012 ORIGINAL ARTICLESThe dietary intake of vitamin A as b-carotene, obtained
from the food frequency questionnaire (FFQ), directly corre-
lated with log10LCbC at baseline (r = 0.322, P# .05). FFQ
data at baseline and 6 months were analyzed by repeated
measures (ANOVA) for differences in the percent intake of
fat, vitamin A as retinol equivalents, vitamin A as b-carotene,
physical activity, and screen time. There were no differences
in these measures between the two groups when adjusted for
the total daily caloric intake (data not shown).
Baseline fasting glucose was similar in both lean and OW
children, whereas fasting insulin was higher in the OW
cohort, as expected (P# .05). Also, markers of IR (HOMA-
IR and QUICKI) and b-cell function (AIR) were different be-
tween the lean and OW groups at baseline (P < .05; Table I).
The GDI, which is an integrated measure of insulin secretion
and insulin action, was similar in lean and OW subjects
(P = .2) at baseline. FVJC supplementation reduced
HOMA-IR (P = .014) and enhanced QUICKI (P = .016) in
the OW group compared with placebo group, after
adjusting for percent change in weight (Table IV). FVJC
treatment effect at 6 months compared with placebo
increased the GDI (P = .037) for all subjects, but the
significance was lost when the OW subgroup was analyzed
separately.
Triglyceride concentrations were higher (P = .004) and
HDL concentrations were lower (P = .034) in the OW group
(Table I). FVJC had no effects in lipid concentrations
in the lean group but significantly lowered triglyceride
concentrations (P = .032) in the OW group. The FVJC
groups showed no change in free fatty acid (P = .301) or
HDL cholesterol concentrations (P = .533).
Treatment groups had lower rates of weight gain during
the first 3 months of the study, but this effect was lost in
the second 3 months of the study (Figure 2).
There were no significant treatment effects between groups
for BMI Z score, waist circumference, waist-to-height ratio,
fat mass index, percent body fat, total body fat, and trunk
fat. Treatment effect by univariate ANOVA on the percent
change in abdominal fat mass (in kg) for the entire cohort
at 6 months showed that the placebo group had a 11.2% in-
crease (95% CI, 4.16 to 18.23) as opposed to a 1.47% (95%
CI, 8.31 to 5.37) decrease in the FVJC supplement group
(P = .029).
The OW cohort showed higher HS-CRP (P = .01) and IL-6
(P = .018) levels than the lean controls at baseline (Table I).
However, there were only negligible changes in HS-CRP andInsulin Resistance and Adiposity in Relation to Serum b-CaroteneIL-6 in the OW children at 3 and 6 months in both the FVJC
and placebo groups.
OW children also showed higher leptin (P < .001) and
lower adiponectin (P = .04) and L/A (P# .001) than their
lean counterparts at baseline (Table I). Although there was
no treatment effect of FVJC on leptin and adiponectin per
se, L/A ratio showed a lowering trend (P = .071), when
analyzed by repeated-measures ANOVA adjusting for
percent change in weight for the entire cohort.
There was a strong inverse correlation between LCbC and
HOMA-IR (r =0.500, P = .001), which strengthened over
time at 3 and 6 months, in contrast to SR and RBP4, which
did not correlate with HOMA-IR (Figure 3, A-C). There
were inverse correlations between LCbC and abdominal fat
mass at baseline (r =0.615, P# .001) and 6 months
(r =0.685, P# .001) (Figure 3, E). A direct correlation
between SR and abdominal fat mass was significant only at
baseline (r = 0.429, P# .013), but this significance vanished
at 6 months (r = 0.262, P = .178) for the entire cohort
(Figure 3, F). In contrast, the concentration of RBP4 did
not correlate with abdominal fat mass in either group
(Figure 3, G). There was an inverse correlation between
LCbC and L/A ratio (r =0.596, P = .001) for the entire
cohort, which persisted at 3 and 6 months (Figure 3, D).
The L/A ratio also directly correlated (P = .001) with the
abdominal fat mass (Figure 3, H). Wilcoxon signed ranks
test determined inverse correlations between the percent
change in LCbC and percent change in leptin at 3 months
(Z =2.497, P = .013) and 6 months (Z =2.573, P = .010)
as well as the percent change in abdominal fat mass at 3
months (Z =2.497, P = .013) and 6 months (Z =2.378,
P = .017) for the entire cohort.
Discussion
A previous intervention study using carrot juice, which is rich
in b-carotene, has reported a doubling of plasma all-trans ret-
inoic acid levels without significant increase in retinol.22 Nu-
tritional counseling targeted to increase the consumption of
fruits and vegetables in our study showed an increase in
serum b-carotene in the lean control group, but quite intrigu-
ingly, its level decreased in the OW placebo group. On the
other hand, the 6-month supplementationwith FVJCcapsules
enhanced the serumb-carotene similarly in both lean andOW
children. In sharp contrast, the levels of retinol unexpectedly
decreased in all groups by 6 months of the interventionLevels 61
Figure 3. Pearson correlations between A, D, E, LCbC B, F, SR, and C, G, RBP4, vs A-C, HOMA-IR and D, L/A at baseline (─),
3 mo (- - -), and 6 mo (–$–) and E-H, abdominal fat mass at baseline (─) and 6 mo (–$–). AFM, abdominal fat mass.
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b-carotene in the supplement is equivalent in both groups, but
the differences in dietary response in the lean control vs OW
boys could not be reconciled. Because carotenoid
bioavailability and bioconversion are heavily influenced by
numerous extrinsic and intrinsic factors, including high
interindividual differences due to common genetic
variations in the enzymes responsible for cleavage and
absorption, we cannot speculate on the nature of this
observation.23 Analysis of the FFQ data was only predictive
of serum LCbC at baseline and was not predictive of the
changes in b-carotene, retinol, or LCbC at 6 months.
The FVJC supplementation significantly lowered triglycer-
ides in the OW boys, and this may have played an important
role in improving insulin sensitivity. Animal studies propose
a diet-responsive regulatory network that tightly controls
b-carotene absorption, dietary lipid transport, and intracel-
lular retinoid production through all-trans retinoic acid neg-
ative feedback regulation of the enzyme Bcmo1.24 An
increase in all-trans retinoic acid is thought to downregulate
intestinal lipid absorption by reducing the expression of the
SR-BI (scavenger receptor class B type 1). All-trans retinoic
acid via retinoic acid receptors induces the expression of
the intestinal transcription factor intestine specific homeo-
box. Intestine specific homeobox in turn repressed the
expression of SR-B1 and Bcmo1, thus preventing accumula-
tion of excess b-carotene.25
The current study also shows inverse correlations among
b-carotene, IR, and adipokine ratios at baseline for the entire
cohort, and this correlation strengthened with FVJC supple-
mentation over time. This is in agreement with a recent
cross-sectional analysis of the National Health and Nutrition
Examination Survey 2001-2006 data in adults that report
lower serum carotenoid concentrations in those individuals
with higher HOMA-IR and features of the metabolic syn-
drome, even after controlling for total cholesterol and triglyc-
erides among other potential confounders.26
Although the present study showed a trend toward higher
RBP4 levels in lean vs OW children (P = .084), serum RBP4
was not correlated with HOMA-IR, AIR, GDI, inflamma-
tory markers, and/or measures of adiposity. Intriguingly,
FVJC supplementation for 6 months did not raise retinol
or lower RBP4 levels in the OW cohort despite a reduction
in HOMA-IR as we had initially hypothesized. This suggests
that b-carotene may play a more important role in meta-
bolic gene regulation than RBP4 or retinol itself. Previous
studies in insulin-resistant obese children have shown a re-
duction in the elevated RBP4 by lifestyle intervention,
which includes exercise, even without marked weight loss,
but with improvements in markers of inflammation and in-
sulin sensitivity.8 On the other hand, others have suggested
that the reduction in RBP4 is dependent on the degree of
weight loss.10 In the present study, none of the subjects
achieved significant weight loss ($0.5 BMI Z-score) or in-
creased exercise. However, the improvement in IR in the
FVJC vs placebo in the OW children reached significance
only after adjusting for the percent change in body weightInsulin Resistance and Adiposity in Relation to Serum b-Caroteneand correlated with the enhanced levels of b-carotene.
This suggests that changes in body weight along with mea-
surements of carotenoid and retinoid status are crucial in
RBP4 studies for accurate interpretation of the results.
The beneficial improvements in IR, triglyceride levels, and
abdominal fat attenuation with juice concentrate supple-
mentation opens up new avenues of research to determine
which combination of nutrients may be responsible for the
effects and underscores the need to enhance intake of whole
fruits and vegetables with high carotenoid value and bio-
availability. A single antioxidant vitamin given at high doses
in subjects with high risk of type 2 diabetes may not have
substantial benefits and could even have negative conse-
quences, as seen in previous studies.6
Strengths of the study include the randomized double-
blind placebo-controlled nature of the intervention, the use
of serum markers such as b-carotene to document dietary
compliance, and simultaneous measurement of serum b-car-
otene, retinol, and RBP4 along with markers of adiposity, IR,
and subclinical inflammation. There are also limitations to
the study because of the complex nature of the supplement,
and consequently, we cannot draw definite conclusions in
terms of causality. Other limitations include the fact that
b-carotene is only one of numerous carotenoids and other
phytonutrients present in natural fruits and vegetables, and
this precludes us from drawing definitive conclusions on as-
cribing a role for b-carotene as solely responsible for the
changes observed in adiposity and IR in the present study.
The relatively small sample size, low compliance, and use of
surrogate markers for IR emphasize the pilot nature of this
study. Compliance with the supplement did not differ signif-
icantly within groups. Further, the current study was conducted
only in prepubertal boys, and therefore, extrapolation of the
data to the general pediatric and/or adult population should
be done with caution. Future studies with more sophisticated
measures of IR and abdominal fat distribution in a larger
cohort would be needed to confirm the findings.
Serum b-carotene, and not retinol and/or RBP4, appears
to be promising as a potential marker of insulin sensitivity
and nutritional status, but additional large-scale studies are
needed to validate its usefulness. Although our study suggests
beneficial effects of FVJC in the presence of nutritional coun-
seling on adiposity and IR in prepubertal boys, we caution
that FVJC capsules should not be considered as substitutes
to the daily intake of fresh fruits and vegetables in children. n
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Table II. Baseline clinical and biochemical
characteristics of study subjects by treatment groups*†z
FVJC group (n = 18) Placebo group (n = 21)
Lean, n (%) 5 (12) 8 (20)
OW, n (%) 13 (33) 13 (33)
Age (years) 8.9 (1.4) 9.3 (1.4)
Fat mass index (kg/m2) 8.8 (3.5-11.3) 7.5 (4.4-10.1)
Abdominal fat mass (kg) 2.8 (1.7-3.8) 3.6 (1.6-5.6)
Systolic blood pressure
(mm Hg)
112 (9) 106 (26)
b-carotene (mM) 0.23 (0.15-0.36) 0.19 (0.14-0.25)
Serum retinol (mM) 1.21 (1.06-1.45) 1.27 (1.10-1.60)
LCbC (mM) 0.049 (0.03-0.08) 0.041 (0.03-0.08)
RBP4 (mM) 1.15 (0.48-1.71) 1.28 (0.88-1.28)
Insulin (pM) 81.1 (42.4-127.5) 76.2 (51.2-113.6)
HDL (mM) 1.11 (0.84-1.39) 1.06 (0.87-1.32)
Triglycerides (mM) 0.64 (0.45-0.85) 0.82 (0.42-1.25)
HOMA-IR 2.34 (1.09-3.75) 2.08 (1.41-3.42)
QUICKI 0.35 0.054 0.34 0.035
AIR 593 (240-969) 518 (299-768)
GDI 1.56 0.28 1.45 0.25
HS-CRP (mg/L) 0.73 (0.39-1.62) 0.59 (0.16-2.95)
IL-6 (pg/ml) 1.26 (0.69-1.76) 1.07 (0.64-2.30)
Leptin (ng/mL) 12.3 (5.7-21.9) 10.3 (3.6-26.7)
Adiponectin (mg/mL) 11.9 (10.0-18.2) 10.0 (7.0-13.0)
L/A 1.67 (0.30-2.62) 1.04 (0.31-1.95)
*Mean SD (all appropriate values).
†Median (IQR) (all appropriate values).
zAll P values are nonsignificant.
Table III. Percent change from baseline for b-carotene, SR, RBP4, and RBP4-SR ratio over time by BMI group*
FVJC group Placebo group
Lean OW Lean OW
3 mo 6 mo 3 mo 6 mo 3 mo 6 mo 3 mo 6 mo
b-Carotene 257 93 303 85 286 63 334 57 17 104 23 94 14 63 30 57
Retinol 7.0 11 7.7 8 6.3 7 2.7 6 8.4 12 1.6 9 2.9 8 13.4 6
RBP4 36.9 21 5.6 16 4.6 5 1.9 6 15.2 8 13.9 19 16.4 6 9.4 6
RBP4/SR 29 32 18 15 14 22 3 10 7.4 36 13 17 54 24 28 11
*Least squared mean SE (all appropriate values).
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Figure 1. Studydesign.Hx, history;PE, physical examination;
FFQ, food frequency questionnaire; IVGTT, intravenous
glucose tolerance test; DEXA, Dual-emission X-ray
absorptiometry
Figure 2. Changes in percent actual weight gain from expected (0%) at A, 3 and B, 6 months divided into quartiles for sup-
plement vs placebo groups.
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